FDA grants approval of trilaciclib (Cosela) as adjunct preceding first line chemotherapy for small cell lung cancer

Trilaciclib is a 1st-in-class short-acting CDK4/6 inhibitor which preserves hematopoietic stem cells and enhances immune system function during chemotherapy. Approval was based on three RCTs (n=245) which demonstrated significant reduction in the duration/severity of neutropenia.

Source:

US Food and Drug Administration